Dr. David Graham, associate director for science in the drug safety division of the Food and Drug Administration, by early August had notified his supervisors that a study of Vioxx showed patients on the starting dose had 50 percent greater risk of cardiac arrest than those on competitor Celebrex.
The Food and Drug Administration silenced one of its drug experts who raised safety concerns weeks before Merck &amp; Co. yanked the blockbuster drug Vioxx due to increased risks for heart attack and strokes, the chairman of the Senate Finance Committee said Thurs
Results of clinical studies with one drug in a given class do not necessarily apply to other drugs in the same class, the FDA said.
